The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A Method for Generation Phage Cocktail with Great Therapeutic Potential
Open accessAbstract
BACKGROUND: Bacteriophage could be an alternative to conventional antibiotic therapy against multidrug-resistant bacteria. However, the emergence of resistant variants after phage treatment limited its therapeutic application. METHODOLOGY/PRINCIPAL FINDINGS: In this study, an approach, named "Step-by-Step" (SBS), has been established. This method takes advantage of the occurrence of phage-resistant bacteria variants and ensures that phages lytic for wild-type strain and its phage-resistant variants are selected. A phage cocktail lytic for Klebsiella pneumoniae was established by the SBS method. This phage cocktail consisted of three phages (GH-K1, GH-K2 and GH-K3) which have different but overlapping host strains. Several phage-resistant variants of Klebsiella pneumoniae were isolated after different phages treatments. The virulence of these variants was much weaker [minimal lethal doses (MLD)>1.3×10(9) cfu/mouse] than that of wild-type K7 countpart (MLD = 2.5×10(3) cfu/mouse). Compared with any single phage, the phage cocktail significantly reduced the mutation frequency of Klebsiella pneumoniae and effectively rescued Klebsiella pneumoniae bacteremia in a murine K7 strain challenge model. The minimal protective dose (MPD) of the phage cocktail which was sufficient to protect bacteremic mice from lethal K7 infection was only 3.0×10(4) pfu, significantly smaller (p<0.01) than that of single monophage. Moreover, a delayed administration of this phage cocktail was still effective in protection against K7 challenge. CONCLUSIONS/SIGNIFICANCE: Our data showed that the phage cocktail was more effective in reducing bacterial mutation frequency and in the rescue of murine bacteremia than monophage suggesting that phage cocktail established by SBS method has great therapeutic potential for multidrug-resistant bacteria infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Podschun, R., & Ullmann, U. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.4.589 · Cited by 2,688
Sulakvelidze, A., Alavidze, Z., & Morris, J. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.649-659.2001 · Cited by 1,566
Anderl, J. N., Franklin, M. J., & Stewart, P. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1818-1824.2000 · Cited by 958 · cited 1×
“Treatment of these infections has become ever more difficult due to the prevalent of multidrug-resistant strains [15,16].”
BackgroundDispersing biofilms with engineered enzymatic bacteriophage
Lu, T. K., & Collins, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704624104 · Cited by 895
Ellis, E. L., & Delbrück, M. (1939) · Journal of General Physiology · doi:10.1085/jgp.22.3.365 · Cited by 696
Long-circulating bacteriophage as antibacterial agents.
Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S., & Adhya, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3188 · Cited by 512
Smith, H. W., & Huggins, M. B. (1983) · Microbiology · doi:10.1099/00221287-129-8-2659 · Cited by 436
Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases
Matsuzaki, S., Rashel, M., Uchiyama, J., Sakurai, S., Ujihara, T., Kuroda, M., Imai, S., Ikeuchi, M., Tani, T., Fujieda, M., et al. (2005) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-005-0408-9 · Cited by 409
Fu, W., Forster, T., Mayer, O., Curtin, J. J., Lehman, S. M., & Donlan, R. M. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00669-09 · Cited by 362
Bacteriophages show promise as antimicrobial agents
Alisky, J., Iczkowski, K., Rapoport, A., & Troitsky, N. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)92874-2 · Cited by 318
Experimental Phage Therapy against Staphylococcus aureus in Mice
Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., & Iannelli, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01513-06 · Cited by 300
Phage therapy: Facts and fiction
Skurnik, M., & Strauch, E. (2006) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2005.09.002 · Cited by 296
Taking aim on bacterial pathogens: from phage therapy to enzybiotics
Hermoso, J. A., García, J. L., & García, P. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.08.002 · Cited by 251
Biocontrol of Escherichia coli O157 with O157-Specific Bacteriophages
Kudva, I. T., Jelacic, S., Tarr, P. I., Youderian, P., & Hovde, C. J. (1999) · Applied and Environmental Microbiology · doi:10.1128/aem.65.9.3767-3773.1999 · Cited by 247
Quantitative Models of In Vitro Bacteriophage–Host Dynamics and Their Application to Phage Therapy
Cairns, B. J., Timms, A. R., Jansen, V. A. A., Connerton, I. F., & Payne, R. J. H. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000253 · Cited by 227
Toward rational control of Escherichia coli O157:H7 by a phage cocktail
Tanji, Y., Shimada, T., Yoichi, M., Miyanaga, K., Hori, K., & Unno, H. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1438-9 · Cited by 226
Tsay, R.-W., Siu, L. K., Fung, C.-P., & Chang, F.-Y. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.9.1021 · Cited by 220
Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., Uchiyama, J., Sakurai, S., Matsuzaki, S., Imai, S., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00635-06 · Cited by 206
Tanji, Y., Shimada, T., Fukudomi, H., Miyanaga, K., Nakai, Y., & Unno, H. (2005) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.100.280 · Cited by 196
Chhibber, S., Kaur, S., & Kumari, S. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.2008/002873-0 · Cited by 194
Gu, J., Xu, W., Lei, L., Huang, J., Feng, X., Sun, C., Du, C., Zuo, J., Li, Y., Du, T., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01144-10 · Cited by 174
Self-citationVerma, V., Harjai, K., & Chhibber, S. (2009) · Current Microbiology · doi:10.1007/s00284-009-9430-y · Cited by 151
Isolation and Characterization of Novel Giant Stenotrophomonas maltophilia Phage φSMA5
Chang, H.-C., Chen, C., Lin, J., Shen, G., Chang, K., Tseng, Y.-H., & Weng, S.-F. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.3.1387-1393.2005 · Cited by 134
Phage therapy—advantages over antibiotics?
Pirisi, A. (2000) · The Lancet · doi:10.1016/s0140-6736(05)74059-9 · Cited by 130
Verma, V., Harjai, K., & Chhibber, S. (2010) · Biofouling · doi:10.1080/08927014.2010.511196 · Cited by 120
Bacteriophage Therapy ofSalmonella enterica:A Fresh Appraisal of Bacteriophage Therapy
Capparelli, R., Nocerino, N., Iannaccone, M., Ercolini, D., Parlato, M., Medaglia, C., & Iannelli, D. (2009) · The Journal of Infectious Diseases · doi:10.1086/648478 · Cited by 120
Verma, V., Harjai, K., & Chhibber, S. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp360 · Cited by 120
Brahams, D. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92844-7 · Cited by 97
Bacteriophage Therapy: Exploiting Smaller Fleas
Deresinski, S. C. (2009) · Clinical Infectious Diseases · doi:10.1086/597405 · Cited by 91
Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Donovan, D. M. (2007) · Recent Patents on Biotechnology · doi:10.2174/187220807780809463 · Cited by 84
Effect of Phage on the Infectivity of Vibrio cholerae and Emergence of Genetic Variants
Zahid, M. S. H., Udden, S. M. N., Faruque, A. S. G., Calderwood, S. B., Mekalanos, J. J., & Faruque, S. M. (2008) · Infection and Immunity · doi:10.1128/iai.00578-08 · Cited by 77
Capparelli, R., Ventimiglia, I., Roperto, S., Fenizia, D., & Iannelli, D. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01340.x · Cited by 58
Development of an Anti- Salmonella Phage Cocktail with Increased Host Range
Zhang, J., Kraft, B. L., Pan, Y., Wall, S. K., Saez, A. C., & Ebner, P. (2010) · Foodborne Pathogens and Disease · doi:10.1089/fpd.2010.0621 · Cited by 35
Cited by
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy
Oechslin, F. (2018) · Viruses · doi:10.3390/v10070351 · Cited by 594
Genetically Engineered Phages: a Review of Advances over the Last Decade
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J., & Lu, T. K. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00069-15 · Cited by 427
Shariati, A., Arshadi, M., Khosrojerdi, M. A., Abedinzadeh, M., Ganjalishahi, M., Maleki, A., Heidary, M., & Khoshnood, S. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1025633 · Cited by 337
Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
Chegini, Z., Khoshbayan, A., Taati Moghadam, M., Farahani, I., Jazireian, P., & Shariati, A. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00389-5 · Cited by 321
Metadata
- Authors
- Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., Zhao, H., Gao, Y., Song, J., Lu, R., Sun, C., & Feng, X.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-01
- Volume
- 7
- Issue
- 3
- Pages
- e31698
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2111538183
- Cited by
- 268
- References
- 33
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.